2022 年 39 巻 5 号 p. 782-785
In recent years, new treatments such as molecular targeted drugs and tumor vaccine therapy have appeared and progressed rapidly. However the treatment of brain tumors and granulomatous disease in the brain represents serious unmet needs due to lethal progression and the blood–brain barrier. The improvements in clinical trial designs and therapeutic drugs overcome these problems. In this article we will focus on glioma, brain metastases and neurosarcoidosis and introduce the promising results in clinical trials of new–targeted therapies with some reports published in 2021.